Metastatic Breast Cancer
Pertuzumab is indicated, in combination with trastuzumab and docetaxel, for patients with HER2-positive metastatic or locally recurrent inoperable breast cancer who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.
Early-Stage Breast Cancer
Pertuzumab is indicated, in combination with trastuzumab and chemotherapy*, for:
Neoadjuvant treatment of patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer at high risk of recurrence (defined as either a tumor diameter > 2 cm or positive lymph nodes) as part of a comprehensive treatment regimen for early-stage breast cancer.
Adjuvant treatment of patients with early-stage HER2-positive breast cancer at high risk of recurrence.
Biological - Monoclonal antibody.
Anti-HER2.
Oncology.
Sold by prescription only.
A Bionovis is a pioneer in the production and commercialization of biological and biosimilar medicines.
Our search for scientific innovations and highly complex medicines aims to build a healthier Brazil and world for everyone.
© 2026 Bionovis. Companhia Brasileira de Biotecnologia Farmacêutica.
